

# Strategic performance report

**Strategic delivery:**       Setting standards       Increasing and informing choice       Demonstrating efficiency economy and value

## Details:

Meeting      Authority

Agenda item      6

Paper number      HFEA (11/05/2016) 793

Meeting date      11 May 2016

Author      Helen Crutcher, Project Risk and Performance Manager

## Output:

For information or decision?      For information

Recommendation      The Authority is asked to note and comment on the latest strategic performance report.

Resource implications      In budget

Implementation date      Ongoing – strategic period 2014-2017

Communication(s)      CMG reviews performance in advance of each Authority meeting, and their comments are incorporated into this Authority paper.

The Department of Health reviews our performance at a formal accountability meeting every quarter (based on the CMG paper).

The Authority receives this summary paper at each meeting, enhanced by additional reporting from Directors. Authority's views are fed back to the subsequent CMG performance meeting.

Organisational risk       Low       Medium       High

Annexes      Annex 1: Strategic performance report – February data

---

## 1. Introduction

- 1.1. The attached paper summarises the main performance indicators, following discussion by the Corporate Management Group (CMG) at its April performance meeting.
- 1.2. Most of the data relates to the position at the end of February 2016. Two parts cover the period ending 31 March 2016 - these are the finance and strategic delivery totaliser sections. These therefore give an end-of-year view for the 2015/16 financial and strategic year.
- 1.3. One presentation change has been made in the report following CMG discussion. The eSET graph has been updated to show the relative percentages of eSET for NHS and private treatment, rather than the overall percentage of treatments that are eSET, divided by funding type. This relative approach gives a clearer picture of eSET provision, given that the number of overall cycles completed in the private sector is significantly higher than the number of NHS cycles.
- 1.4. Overall performance is good, with a single performance indicator in the red, and we are making good progress towards our strategic aims.

---

## 2. Recommendation

- 2.1. The Authority is asked to note the latest strategic performance report.


# Annex A - HFEA strategic performance scorecard

## 1. Summary section

### Dashboard – February data


#### Strategic delivery totaliser

(see overleaf for more detail)




#### Setting standards:

critical and major recommendations on inspection




#### Increasing and informing choice:

public enquiries received (email)




#### Overall performance - all indicators:



(See RAG status section for detail.)


#### Efficiency, economy and value: Budget status: cumulative surplus/(deficit)

This graph details our net position as at 31 March 2016 (month 12) and our actual year end outturn. The graph shows we performed better than budget ie, we have ended the year at a surplus. The components making up the surplus/deficit are shown in the 'budget status' section by two graphs (income and expenditure).



## Dashboard - Commentary

### Strategic delivery (to end of March) – summary:



It was previously necessary to re-cast the timeline for the beta phase of IfQ, which is still in progress. Earlier delays have contributed to us appearing 'behind' on the above graph compared with the original plan. However we have now started to see the 'earned value' of IfQ improving, and over the next few months we expect to see greater convergence between the delivery line and the elapsed timeline in the above graph, especially once beta has been completed and the remaining GDS gateways have been passed. Very little was due for delivery in January and February, so the apparent dip in those months is not a cause for concern. In contrast, a number of business plan items that contribute to strategic delivery were due for completion at the end of the business year, which has improved the overall picture.

CMG's assessment of end of year delivery was that a majority of planned work was either partially or fully delivered in 2015/16. A minority has been carried forward into 2016/17, either because of tie-ins with IfQ products (and the revised timeline for beta delivery), or because it became clear during the year that

some elements of the work would need to be longer term, were more extensive than originally envisaged, or should be re-considered in light of in-year changes or likely future developments.

For the purposes of this totaliser, where there was good progress based on the original intentions in the 2015/16 business plan, this work has been counted as 'delivered'. Where items have been rescheduled into 2016/17 in their entirety, because of the link with IfQ, these have been counted as 'not delivered' in 2015/16 (but will be counted in a few months' time when the new delivery date is reached). Some items were cancelled in-year owing to other changes, and these were counted as 'not delivered'. The end of year (final quarter) progress against milestones due is described below.

## **Strategic delivery for January to March:**

### **Setting standards**

In January, a report was made to CMG summarising information gathered from the most recent meeting of the EU competent authorities, which took place in December. The purpose of reporting back is to demonstrate that we continue to fulfil our role as an EU competent authority, and to ensure that CMG is sighted on information that will inform our approach to high quality regulation and may result in internal projects.

We began, some time ago, to include more explicit information about patient experiences in inspection reports to licensing committees. However, building on this work further will require completion of the new Choose a Fertility Clinic function, which will be one of the key outputs of the IfQ programme in 2016/17. When delivered (July 2016), this work will also address our aim to improve the presentation of our data, so as to drive continued improvement in success rates and improved value for money for patients. Clinics already receive performance alerts in relation to success rates, and the HFEA has continued throughout the year to review emerging procedures and to consider and publish evidence.

The HFEA also explored with professional stakeholders the issue of acknowledging that treatment is often unsuccessful. We remain keen to see clinics putting better support in place for patients when treatment is unsuccessful. During this year we have been developing our new website, which will provide more information for prospective patients, so as to ensure that they enter treatment with a realistic understanding of their chances of success, and more signposting information for patients who have experienced unsuccessful treatment.

The HFEA has continued to work with the Lifecycle campaign, making a range of information leaflets available so as to ensure that potential donors, recipients and donor conceived people have better access to clear, authoritative impartial information about a range of issues. The leaflets, together with the pack about donor information produced earlier for clinics, and the new provision of our counselling support service (from June 2015 onwards), have improved role clarity for clinics in relation to donation and information guardianship. We believe this set of actions contributes to an improved experience for donors, donor-conceived people seeking information, and patients and their families.

In March, the HFEA also attended the Association of Fertility Patient Organisations (AFPO) standing stakeholder group meeting, to engage with patients and donor organisations.

## Increasing and informing choice

Following the rescheduling of IfQ beta phase work, no final deliverables were due in this area during January to March. However, the majority of the new content and templates for the website have been successfully developed, with the aim of ensuring that patients will have access to high quality meaningful information.

By year-end, the HFEA had also completed significant user research to inform the IfQ Programme, especially to clarify what patients view as the key indicators of quality in treatment. This research has underpinned our approach to developing the new CaFC. Patients' views have been, and will continue to be, integrated into our ways of working and our future plans for the new website.

Through collaborative working with stakeholders and NHS Choices, we have made significant progress with ensuring that patients consistently get good early advice and appropriate referral, regardless of the fertility knowledge of their particular GP. This has been underlined by our user research and is fundamental to the 'user journeys' that are now being implemented in our new website.

We also set an objective of ensuring that clinics give accurate and sufficient information to patients in their websites and literature. During renewal inspections, we ask patients directly about these points, and we conduct desk-based research to provide factual feedback to clinics and encourage best practice.

During the 2015/16 business year, we started to consider how we might work with NHS commissioning bodies to help them to commission the best services for patients using available data. Some of this work will need to follow on from IfQ, since it relies on being able to make more use of our data. A draft guide for commissioners was developed and road tested with the multiple births stakeholder group in 2015/16. A deeper look at commissioning is likely to form part of our strategy for 2017-2020.

In March we published our 'Fertility treatment in 2014' report, covering treatments in 2013-2014, including a statistical report on donation and donor conception. We launched this publication at our Annual Conference on 24 March.

## Efficiency, economy and value

Based on the original IfQ timeline, the cleansing of 'priority one' data in preparation for data migration should have been completed this month. Owing to prior resource pressures, the volume of cleansing work needed, and the changes made to the timeline for IfQ, this work is still ongoing into 2016/17. Good progress is being made on HFEA-based cleansing (important in reducing the burden of cleansing for clinics). Clinic based cleansing is starting up now, and the process and rationale for this were explained to delegates at the Annual Conference.

Since overall IfQ beta phase delivery was re-timed to the summer, the completion of the clinic portal (release one), website and CaFC, will be carried forward into 2016/17. However a great deal of work has been done during 2015/16, including good progress towards user testing for a public beta phase of the website (which was completed in April 2016).

Alongside continuing IfQ programme delivery, we have maintained the existing Register of treatments and outcomes, throughout the year, so as to ensure that patients and others have ongoing access to high quality information. This also ensures that we continue to have high quality data available to help us to deliver new patient information and publications, and to support risk-based regulation and evidence-based policy-making.

We have continued to maintain our shared services and collaborative arrangements so that we are efficient, and perpetuate savings made in earlier years. This helps us to achieve measurable 'added value' and demonstrate our internal efficiency.

Our accountability to the sector for fee rates was maintained through the continuing Fees Group, which enables us to evidence the value of what we do in return for the fees paid by clinics. This group has become well established and is working effectively.

## Red/amber/green status of performance indicators as at February 2016

The single red key performance indicator (KPI) shown in the 'overall status - performance indicators' pie chart on the dashboard is as follows:

The number of working days from the day of inspection to the day the draft report is sent to the PR has a target of 90% in 20 working days. In February, performance was at 22% - much lower than expected, with seven reports missing the target. Four reports were sent within 7 days of the target. Three reports took longer, up to 39 working days. A report outstanding from January was sent at 63 working days, and there are still two reports which remain outstanding for February which will be followed up in next month's strategic performance report.


Reasons for delays are varied, but mainly relate to either workload or complexity (or both), or sometimes because legal advice is needed. The team always prioritises robustness and quality over speed. The team's performance in this area is managed closely, and breaches are always known and managed at the time they occur, in their own particular context.

No projects were on a red risk rating in February.




## Budget status – March data

The dashboard shows the overall surplus/deficit position. The graphs below show how the surplus or deficit has arisen. These figures are updated quarterly, approximately one month after the end of each quarter.



This graph shows our budgeted (planned) licence fee income and grant-in-aid (GIA) compared to what is actually happening.

As of month 12 (31 March 2016) we have exceeded our budget (a significant surplus of £436k).



This graph is the second component that makes up the surplus/deficit. This excludes costs relating to IfQ, since this is being funded from reserves and accounted for separately.

Our actual outturn (year-end position) shows an underspend on expenditure of over £300k. This underspend has been helped by inclusion of receipts from legal cases where we were awarded costs. Our year end position has also been impacted by underspends within salaries and other staff costs. The Strategy and Corporate Affairs directorate has ended the year under spending in key areas such as the Annual Conference and publications.

## Quality and safety of care

As agreed previously, the following items are most meaningful when reported on an annual basis. The following items will continue to be presented to the Authority each year in September:


- number of risk tool alerts (and themes)
- common non-compliances (by type)
- incidents report (and themes).

The following figures and graphs were run on 4 April 2016.

### eSET split by private/NHS:

Funding	Year						
	2010	2011	2012	2013	2014	2015	2016
<b>NHS Funded:</b>							
Recorded as eSET	4294	4903	6264	7868	8443	9725	2774
	7%	8%	10%	13%	13%	15%	18%
Not recorded as eSET	19283	19491	17869	17719	17830	16906	3801
	33%	32%	30%	29%	28%	26%	24%
<b>Private:</b>							
Recorded as eSET	3422	4629	5699	6857	7736	9309	2576
	6%	8%	9%	11%	12%	14%	17%
Not recorded as eSET	31021	31546	30398	29391	29536	29234	6458
	53%	52%	50%	48%	46%	45%	41%

Graph: eSET relative % trends NHS/private:




**Explanatory text:** Showing the total of all reported IVF treatment forms and counting those that the clinics recorded as eSET

As of February data, we have updated the graph to display the relative percentages of eSET for NHS and privately funded cycles, rather than the percentage of all treatments as was previously shown. This relative approach gives a clearer picture, given that the number of overall cycles completed in the private sector is significantly higher than the number of NHS cycles. We have retained the raw figures in the table, so that the 'all treatment' numbers can still be seen as well.

**Unfiltered success rates as % - pregnancies (rather than outcomes, since this provides a better real-time picture):**

Years	All cycles	Pregnancies	Pregnancy rate %
2010	58020	16117	27.78
2011	60569	16896	27.9
2012	60230	17453	28.98
2013	61835	18648	30.16
2014	63545	19875	31.28
2015	65174	20445	31.37
2016	15609	2565	16.43








**Graph showing the pregnancy rate over recent years**

**Explanatory text:** Looking at all IVF treatment forms, and providing a count of pregnancies - as recorded on the early outcome form. 2016 figures are in grey since it is still quite early in the year, and there is always a lag in reporting pregnancies.

## 2. Indicator section

### Key performance and volume indicators – February data:

Indicator	Performance	RAG	Recent trend <sup>1</sup>	Aim <sup>2</sup>	Notes
<b>Setting standards: improving the quality and safety of care through our regulatory activities.</b>					
<b>Licensing decisions made:</b> - By ELP - By Licence Committee	11 0			No KPI – tracked for workload monitoring purposes	Volume indicator (no KPI target).
<b>Setting standards: improving the lifelong experience for donors, donor-conceived people, patients using donor conception, and their wider families.</b>					
<b>Percentage of Opening the Register requests responded to within 20 working days</b>	100% (23)			Maintain at 100% 	KPI: 100% of complete OTR requests to be responded to within 20 working days (excluding counselling time)

<sup>1</sup> Blue dashed line in graphs = KPI target level. This line may be invisible when performance and target are identical (eg, 100%).

<sup>2</sup> Direction in which we are trying to drive performance. (Are we aiming to exceed, equal, or stay beneath this particular KPI target?)

Indicator	Performance	RAG	Recent trend <sup>1</sup>	Aim <sup>2</sup>	Notes
-----------	-------------	-----	---------------------------	------------------	-------


**Increasing and informing choice: using the data in the Register of Treatments to improve outcomes and research.**

See graphs focused on quality of outcomes – after dashboard page.

**Increasing and informing choice: ensuring that patients have access to high quality meaningful information.**

**Number of visits to the HFEA website (compared with previous year)**  
 (trend arrow indicates movement since previous month)

129,156  
(132,132)




No KPI – tracked for general monitoring purposes.  
 Volume indicator showing general website traffic compared to the same period in previous year. Measured on the basis of 'unique visitors'.

**Efficiency, economy and value: ensuring the HFEA remains demonstrably good value for the public, the sector and Government.**

**Average number of working days taken for the whole licensing process, from the day of inspection to the decision being communicated to the centre.**

69 working days




KPI: Less than or equal to 70 working days.  
 Maintain at 70wd or less

Indicator	Performance	RAG	Recent trend <sup>1</sup>	Aim <sup>2</sup>	Notes
<p>Monthly percentage of PGD applications processed within three months (66 working days).</p> <p>Average number of working days taken.</p>	<p>100%</p> <p>56</p>	<p>★</p> <p>★</p>		<p>Maintain 100%</p>	<p>KPI: 100% processed (i.e. considered by LC/ELP) within three months (66 working days) of receipt of completed application.</p>
<p>Annualised (rolling year) percentage of PGD applications processed within three months (66 working days)</p> <p>Average number of working days taken.</p>	<p>100%</p> <p>49</p>	<p>★</p> <p>★</p>		<p>Maintain 100%</p>	<p>KPI: As above. (Annualised score). Performance has reached target, and the annualised figure, which earlier was adversely affected by some complex multi-type applications received during the rolling year, has attained 100%.</p>

Indicator	Performance	RAG	Recent trend <sup>1</sup>	Aim <sup>2</sup>	Notes
-----------	-------------	-----	---------------------------	------------------	-------

Number of requests for contributions to Parliamentary questions

Total = 18




No KPI – tracked for general monitoring purposes.

Volume indicator. Last year's numbers were notably high. Many of those PQs related to the work we were then doing on mitochondria. The recent approval of research using the CRISPR-Cas9 gene editing technique has led to multiple requests about this subject.

Number of Freedom of Information (FOI), Environmental Information Regulations (EIR) requests and Data Protection Act (DPA) requests

6



No KPI – tracked for general monitoring purposes.

Volume indicator. There does not appear to be any trend or predictability in the volume or focus of our FOI (and other) requests.

Indicator	Performance	RAG	Recent trend <sup>1</sup>	Aim <sup>2</sup>	Notes														
Staff sickness absence rate (%) per month.	3.2%	↔	<table border="1"> <caption>Staff Sickness Absence Rate (%)</caption> <thead> <tr> <th>Month</th> <th>Rate (%)</th> </tr> </thead> <tbody> <tr> <td>Sep</td> <td>2.2%</td> </tr> <tr> <td>Oct</td> <td>2.8%</td> </tr> <tr> <td>Nov</td> <td>2.9%</td> </tr> <tr> <td>Dec</td> <td>2.4%</td> </tr> <tr> <td>Jan</td> <td>3.2%</td> </tr> <tr> <td>Feb</td> <td>3.2%</td> </tr> </tbody> </table>	Month	Rate (%)	Sep	2.2%	Oct	2.8%	Nov	2.9%	Dec	2.4%	Jan	3.2%	Feb	3.2%	<p>Maintain 2.5% or less</p>	<p>KPI: Absence rate of ≤ 2.5%. Public sector sickness absence rate average is eight days lost per person per year (3.0%).</p>
Month	Rate (%)																		
Sep	2.2%																		
Oct	2.8%																		
Nov	2.9%																		
Dec	2.4%																		
Jan	3.2%																		
Feb	3.2%																		

**Commentary:** The current absence rate has risen above the KPI, but this is due mainly to long-term sick leave and seasonal illnesses. This has been investigated and does not demonstrate a trend towards problematic sickness absence, though we will continue to monitor this.

Cash and bank balance	£2,378k	↓	<table border="1"> <caption>Cash and Bank Balance (£k)</caption> <thead> <tr> <th>Month</th> <th>Balance (£k)</th> </tr> </thead> <tbody> <tr> <td>Oct</td> <td>£2,458</td> </tr> <tr> <td>Nov</td> <td>£2,360</td> </tr> <tr> <td>Dec</td> <td>£2,557</td> </tr> <tr> <td>Jan</td> <td>£2,185</td> </tr> <tr> <td>Feb</td> <td>£2,378</td> </tr> <tr> <td>Mar</td> <td>£2,157</td> </tr> </tbody> </table>	Month	Balance (£k)	Oct	£2,458	Nov	£2,360	Dec	£2,557	Jan	£2,185	Feb	£2,378	Mar	£2,157	<p>Reduce</p>	<p>KPI: To move closer to minimum £1,520k cash reserves (figure agreed with DH).  <b>Commentary:</b> March's balance is approximately 9% below February's levels, helped by the increase in payment of March purchase invoices. See below for full end-of-year position and commentary.</p>
Month	Balance (£k)																		
Oct	£2,458																		
Nov	£2,360																		
Dec	£2,557																		
Jan	£2,185																		
Feb	£2,378																		
Mar	£2,157																		



Management  
accounts:

## March accounts:

Income & Expenditure Account	Mar-2016					
	Year to Date			Full Year		
	Actual YTD £	Budget YTD £	Variance YTD £	Forecast £	Budget £	Variance £
Accounting Period						
Cost Centre Name						
Department Name						
<b>Income</b>						
Grant-in-aid	1,120	1,120	-	1,120	1,120	-
Licence Fees	4,216	4,120	96	4,564	4,120	445
Other Income	55	6	49	56	6	50
<b>Total Income</b>	<b>5,391</b>	<b>5,246</b>	<b>145</b>	<b>5,740</b>	<b>5,246</b>	<b>495</b>
<b>Revenue costs - Charged to Expenditure</b>						
Salaries	3,654	3,807	- 153	3,608	3,807	- 199
Other Staff costs	221	258	- 37	225	258	- 33
Authority/Committee costs	144	166	- 22	150	166	- 16
Other Compliance costs	56	39	17	61	39	22
Other Strategy costs	100	175	- 75	107	175	- 69
Facilities costs incl non-cash	339	355	- 16	359	355	3
IT costs costs	115	106	9	110	106	4
Legal costs	204	340	- 136	275	340	- 65
Professional Fees	67	67	0	80	68	12
<b>Total Revenue costs</b>	<b>4,900</b>	<b>5,313</b>	<b>- 413</b>	<b>4,975</b>	<b>5,314</b>	<b>- 340</b>
<b>Total Surplus/(Deficit) before Capital &amp; Project costs</b>	<b>491 -</b>	<b>67</b>	<b>559</b>	<b>766 -</b>	<b>69</b>	<b>834</b>
<b>Capital &amp; Project - Reserves funded</b>						
IFQ	683	1,100	- 417	633	1,100	- 467
Donor Support	8	20	- 12	8	20	- 12
Other Capital costs	69	100	- 31	69	-	69
<b>TOTAL NET ACTIVITY</b>	<b>760</b>	<b>1,220</b>	<b>- 1,212</b>	<b>641</b>	<b>1,120</b>	<b>- 479</b>

Indicator	Performance	RAG	Recent trend <sup>1</sup>	Aim <sup>2</sup>	Notes
<b>Commentary:</b>	<b>Summarised management accounts – commentary Q4</b>				
	<b>Income</b>				
	January saw treatment fees down against budget by 3%, with February turning around and up by 1%. March saw a positive increase against budget of 2% (£96k). We believe this is due to clinics submitting data late due to issues with submissions in earlier months.				
	Our year end outturn (actual result) resulted in a 3% increase on budget. We drew down our full grant-in-aid (GIA) for both revenue and capital.				
	<b>Expenditure</b>				
	In January we overspent by 1% against budget with overspends in the areas of other staff costs (T&S) within the Compliance directorate, IT and legal costs.				
	February saw an improvement with underspends totalling £32k, around 8%. There were underspends within salaries, Authority and Committee costs.				
	At year-end (March 2016), we underspent on our expenditure by 2% (£23k). Salaries due to vacancies were under spent by 4% and were the main reason for this. There were smaller underspends across directorates. Our legal costs were significantly down against budget due to receipts from cases won over the year.				
	<b>IfQ and other project costs</b>				
	The costs of IfQ at year-end were removed from the Income and Expenditure Account and transferred to the Balance Sheet. This is because these costs are being capitalised. This means that they will be amortised (released) over a period of time. This is in line with our policy to capitalise anything that releases economic benefit for more than a year.				
	The year-end position for IfQ was a total cost of £638k which is largely made up of developer/project management and the cost of building the key components of IfQ. The project is expected to incur costs in Q1-3 of the 2016/17 business year. It is expected that these too will be capitalised.				

## IfQ indicators: February update for Beta project phase

Frequency / trigger point	Metric	Purpose	Latest status:						
At programme set-up / major reorganisation / new tranche	MSP health check overall score achieved / maximum score as a %	Is the programme set up to deliver?	<p><b>January/February update:</b> The MSP health check process was commenced, with interviews taking place with a range of key internal stakeholders. (Final interviews subsequently took place at the end of March 2016, with the final report to be completed by end April 2016.)</p>						
Monthly	Timescales: Sprint progress and estimate of remaining work.	Is there scope creep/over-run?	<p><b>January/February update:</b> Work has progressed well through sprints two to sprint seven. There have been continued challenges progressing through the work according to schedule, with the trend of work running over to the following sprint continuing. This has increased the pressure on the last sprints of beta and may have further consequences on the features that are brought forward to user testing and DH/GDS Assessment. This issue is discussed regularly at IfQ Programme Board (which meets monthly).</p>						
Monthly	Resource usage: The total number of days Reading Room are contracted to provide, vs the number of days consumed to date.	To monitor the rate of resource usage.	<p><b>January/February updates</b> Reading Room had a total of 257 days allocated to IfQ at HFEA, for Release 1 Beta. This does not include days to be allocated to user testing activities. A total of 215 days have been consumed to the end of beta sprint 6, with 42 days remaining.</p> <div data-bbox="833 903 2076 1327" data-label="Figure"> <p style="text-align: center;">Reading Room Resource - Beta Days Consumed vs Remaining</p> <table border="1"> <caption>Reading Room Resource - Beta Days Consumed vs Remaining</caption> <thead> <tr> <th>Category</th> <th>Days</th> </tr> </thead> <tbody> <tr> <td>Days Consumed Beta</td> <td>215</td> </tr> <tr> <td>Days Remaining Beta</td> <td>42</td> </tr> </tbody> </table> </div>	Category	Days	Days Consumed Beta	215	Days Remaining Beta	42
Category	Days								
Days Consumed Beta	215								
Days Remaining Beta	42								

## IfQ indicators: February update for Beta project phase

Frequency / trigger point	Metric	Purpose	Latest status:																																							
			<p>The below graph shows days consumed by sprint, against a pro-rata trend of those days divided equally by the number of sprints in Beta. At the current rate of resource usage, Reading Room will have consumed all their estimated days by the end of Sprint 7. Due to the nature of the capped time and resource contract with Reading Room, they are contractually required to continue building the Beta product at their own cost. This may lead to some requirement for further contractual conversations with Reading Room.</p> <table border="1"> <caption>Reading Room Resource Beta Burndown Chart (Days)</caption> <thead> <tr> <th>Sprint</th> <th>Cumulative days consumed</th> <th>Available days pro-rata</th> </tr> </thead> <tbody> <tr><td>Sprint 1</td><td>20</td><td>21</td></tr> <tr><td>Sprint 2</td><td>59</td><td>43</td></tr> <tr><td>Sprint 3</td><td>97</td><td>64</td></tr> <tr><td>Sprint 4</td><td>129</td><td>86</td></tr> <tr><td>Sprint 5</td><td>174</td><td>107</td></tr> <tr><td>Sprint 6</td><td>215</td><td>129</td></tr> <tr><td>Sprint 7</td><td>150</td><td></td></tr> <tr><td>Sprint 8</td><td>171</td><td></td></tr> <tr><td>Sprint 9</td><td>193</td><td></td></tr> <tr><td>Sprint 10</td><td>214</td><td></td></tr> <tr><td>Sprint 11</td><td>236</td><td></td></tr> <tr><td>Sprint 12</td><td>257</td><td></td></tr> </tbody> </table>	Sprint	Cumulative days consumed	Available days pro-rata	Sprint 1	20	21	Sprint 2	59	43	Sprint 3	97	64	Sprint 4	129	86	Sprint 5	174	107	Sprint 6	215	129	Sprint 7	150		Sprint 8	171		Sprint 9	193		Sprint 10	214		Sprint 11	236		Sprint 12	257	
Sprint	Cumulative days consumed	Available days pro-rata																																								
Sprint 1	20	21																																								
Sprint 2	59	43																																								
Sprint 3	97	64																																								
Sprint 4	129	86																																								
Sprint 5	174	107																																								
Sprint 6	215	129																																								
Sprint 7	150																																									
Sprint 8	171																																									
Sprint 9	193																																									
Sprint 10	214																																									
Sprint 11	236																																									
Sprint 12	257																																									

## IfQ indicators: February update for Beta project phase

Frequency / trigger point	Metric	Purpose	Latest status:
Monthly	Cost: earned value (% complete * estimated spend at completion)	Is the spend in line with milestone delivery?	<p>There are four things we can attribute value to: websites and CaFC; Clinic Portal; the Register and internal systems; defined dataset, discovery, stakeholder engagement etc. 25% of the value of the 1.8M programme cost at completion has been attributed to each project.</p> <p><b>January/February update:</b> The graph below indicates that the earned value has been increasing since Beta started in December.</p>

## IfQ indicators: February update for Beta project phase


Frequency / trigger point

Metric


Purpose

Latest status:

At this stage we are not expecting any significant spend until the end of Beta currently scheduled for June 2016. The following graph shows the earned value starting to increase in January/February. In the separate IfQ item on the agenda, the Authority will receive an update on progress for March.



## IfQ indicators: February update for Beta project phase

Frequency / trigger point	Metric	Purpose	Latest status:															
Monthly	Stakeholder engagement: combined stakeholder engagement score (internal plus external stakeholder events or communications)	Are we keeping stakeholders with us? Is it getting better or worse?	<p><b>January:</b> We held two show and tell sessions in January which were well attended by staff. We updated the IfQ intranet pages and distributed some snippets to keep colleagues up to date.</p> <p>The IfQ stakeholder group didn't take place in January as we decided there wasn't enough to share with them at this point in the project.</p> <p>Total combined score = 2</p> <p><b>February:</b> The IfQ stakeholder group took place in February and went through some of the draft website content. We held one show and tell session.</p> <p>Total combined score = 2</p>															
Monthly	Risks: sum of risk scores (L x I)	Is overall risk getting worse or better (could identify death by a thousand cuts)?	<p><b>January/February update:</b> The below line graph represents the overall IfQ risk score, which combines the perceived impact and likelihood of the current risks on hand each month. The overall risk score for the IfQ Programme has increased.</p>  <table border="1"> <caption>Risk Score Data</caption> <thead> <tr> <th>Month</th> <th>Inherent Risk Score</th> <th>Residual Risk Score</th> </tr> </thead> <tbody> <tr> <td>Dec-15</td> <td>158</td> <td>38</td> </tr> <tr> <td>Jan-16</td> <td>106</td> <td>23</td> </tr> <tr> <td>Feb-16</td> <td>114</td> <td>28</td> </tr> <tr> <td>Mar-16</td> <td>119</td> <td>33</td> </tr> </tbody> </table>	Month	Inherent Risk Score	Residual Risk Score	Dec-15	158	38	Jan-16	106	23	Feb-16	114	28	Mar-16	119	33
Month	Inherent Risk Score	Residual Risk Score																
Dec-15	158	38																
Jan-16	106	23																
Feb-16	114	28																
Mar-16	119	33																

## IfQ indicators: February update for Beta project phase

Frequency / trigger point	Metric	Purpose	Latest status:																																										
			<p>The major risks score are associated with resources, development, timescale, business continuity and data security.</p> <table border="1"> <caption>Risk Scores by Category</caption> <thead> <tr> <th>Category</th> <th>Score</th> <th>Risk Level</th> </tr> </thead> <tbody> <tr><td>Programme</td><td>1</td><td>Insignificant</td></tr> <tr><td>Operational</td><td>1</td><td>Insignificant</td></tr> <tr><td>Data security</td><td>1</td><td>Insignificant</td></tr> <tr><td>Business Continuity</td><td>1</td><td>Insignificant</td></tr> <tr><td>Service transition</td><td>1</td><td>Insignificant</td></tr> <tr><td>Stakeholder Engagement</td><td>1</td><td>Insignificant</td></tr> <tr><td>Clinic Costs</td><td>1</td><td>Insignificant</td></tr> <tr><td>Reputation</td><td>2</td><td>Minor</td></tr> <tr><td>Design</td><td>2</td><td>Minor</td></tr> <tr><td>Timescales</td><td>3</td><td>Moderate</td></tr> <tr><td>Development</td><td>3</td><td>Moderate</td></tr> <tr><td>Quality</td><td>4</td><td>Major</td></tr> <tr><td>Resources</td><td>4</td><td>Major</td></tr> </tbody> </table>	Category	Score	Risk Level	Programme	1	Insignificant	Operational	1	Insignificant	Data security	1	Insignificant	Business Continuity	1	Insignificant	Service transition	1	Insignificant	Stakeholder Engagement	1	Insignificant	Clinic Costs	1	Insignificant	Reputation	2	Minor	Design	2	Minor	Timescales	3	Moderate	Development	3	Moderate	Quality	4	Major	Resources	4	Major
Category	Score	Risk Level																																											
Programme	1	Insignificant																																											
Operational	1	Insignificant																																											
Data security	1	Insignificant																																											
Business Continuity	1	Insignificant																																											
Service transition	1	Insignificant																																											
Stakeholder Engagement	1	Insignificant																																											
Clinic Costs	1	Insignificant																																											
Reputation	2	Minor																																											
Design	2	Minor																																											
Timescales	3	Moderate																																											
Development	3	Moderate																																											
Quality	4	Major																																											
Resources	4	Major																																											
Quarterly	Benefits: value (£) of tangible benefits planned to be delivered by the programme	Is the value of the benefits increasing or decreasing – could trigger a review of the business case?	<p><b>January/February update:</b></p> <p>The benefits realisation value should be reviewed periodically based on the business case; this will be looked at by IfQ Programme Board. No issues have been raised regarding benefits realisation to date.</p>																																										